Further clinical trials in lung cancer should take into account this issue, and use not only Smo-inhibitors (already available in clinic) or Shh antibodies, but also Gli-inhibitors that are in development [76], to correctly cover all the ways of Gli activation. The gene discussed is GLI1; the disease is lung cancer.